Ph II of Cabo. w/ Ipi./Nivo. and TACE in Pts w/ HCC (not candidates for Curative Tx)

Cancer
Farshid Dayyani
Phase II Study of Cabozantinib Combined with Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) Who are not Candidates for Curative Intent Treatment
Liver

Study Description

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

Eligibility

You can participate in this study if you satisfy following criteria:

  • At least 18 years of age
  • Biopsy proven or imaging based diagnosis of hepatocellular carcinoma ("primary liver cancer")
  • Not a candidate for surgery or curative treatment based on your doctor's assessment

You cannot participate in this study if you have any of the following criteria:

  • Previous treatment with cabozantinib or immunotherapy
  • Any active infection (except for controlled Hepatitis B or C) or other cancers
  • Pregnant or nursing
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.